Cencora Inc. stock gains after beating quarterly earnings estimates

Cencora Inc. stock (ISIN US15135B1017) is changing hands at around USD 318.54 on the New York Stock Exchange as of September 17, 2026, supported by stronger than expected quarterly earnings and solid revenue growth in its latest reported period.

Quarterly earnings beat supports valuation

According to MarketBeat, Cencora last reported its quarterly results on August 5, 2026, posting earnings per share (EPS) of USD 4.48 for the quarter against a consensus estimate of USD 4.35, a positive surprise of USD 0.13 per share.

In the same earnings release period, Cencora generated revenue of USD 84.75 billion in that quarter, slightly ahead of consensus expectations of USD 84.31 billion as cited by MarketBeat, with revenue up 5.1 percent year over year compared with the same quarter a year earlier.

The company reported a net margin of 0.79 percent for that quarter and a return on equity of 125.45 percent, highlighting the razor-thin margins typical of large pharmaceutical distributors but also the capital-efficient nature of Cencora’s business model as noted by MarketBeat.

Revenue growth and dividend add to the story

For investors, the 5.1 percent year-over-year revenue increase in the latest quarter is a key signal that Cencora continues to expand volumes and services despite operating with sub-1 percent net margins, which forces management to focus tightly on cost control and working-capital efficiency.

Historical figures from the same source show that in the prior-year quarter Cencora had EPS of USD 4.00, meaning that the latest quarterly EPS of USD 4.48 represents an increase of 12.0 percent compared with the previous year’s period according to MarketBeat.

In addition to earnings growth, Cencora has been returning cash to shareholders through dividends: the company recently paid a quarterly dividend of USD 0.60 per share on August 31, 2026 to shareholders of record as of August 14, 2026, corresponding to an annualized dividend of USD 2.40 and a dividend payout ratio of 17.83 percent, as described by MarketBeat.

Those dividend metrics suggest that Cencora retains the bulk of its earnings to fund operations and potential growth initiatives, while still providing a modest yield to shareholders, which may be attractive to investors seeking exposure to the healthcare supply chain with a combination of income and earnings growth.

Valuation, index context and ownership signals

The current share price around USD 318.54 on September 17, 2026, as reported in a recent price snapshot by MarketBeat, reflects the market’s willingness to assign a high absolute share price to a business with thin margins but strong equity returns and consistent earnings delivery.

Based on information from First Trust Portfolios, Cencora is included in the Capital Strength Opportunity fund with a weighting of 3.92 percent, underlining that some institutional strategies view the company as a core holding within the healthcare sector and large-cap growth style.

Research cited by MarketBeat indicates that analysts currently anticipate full-year EPS of about USD 17.87 for the current fiscal year, implying that the latest quarterly EPS of USD 4.48 is broadly in line with a trajectory of high-teens annual earnings, a factor that helps frame valuation discussions for Cencora’s stock.

Stock price level and investor perspective

Cencora Inc. stock most recently traded around USD 318.54 on the New York Stock Exchange as of September 17, 2026, with this price representing a premium to historical levels driven by the company’s ability to grow EPS from USD 4.00 to USD 4.48 year over year while maintaining revenue growth of 5.1 percent and a net margin below 1 percent.

More news and analyses on Cencora Inc. stock